The allure of achieving incredible gains in short time periods has many investors looking to strike it rich picking biotech stocks. But it's also attracted the attention of many fund companies, which are looking to capitalize on the average investor's interest in a more diversified form of biotech exposure. While my personal preference for the longer-term investor looking to invest in biotech is to target a basket of stocks, in the following video, I offer up an opinion on the biotech ETF that best captures the essence of biotech investing.

If you're a biotech investor interested in finding big winners, Motley Fool co-founder David Gardner's picks have frequently trounced the market. How? Because he's always on the lookout for revolutionary stocks and recommends them before Wall Street catches on to their disruptive potential. If you're interested in how David discovers his winners, click here to get instant access to a personal tour behind David's Supernova service.


The article The Better Way to Play Biotech originally appeared on Fool.com.

Brenton Flynn owns shares of Sarepta Therapeutics. The Motley Fool owns shares of Dendreon. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.

Copyright © 1995 - 2013 The Motley Fool, LLC. All rights reserved. The Motley Fool has a disclosure policy.


Increase your money and finance knowledge from home

Goal Setting

Want to succeed? Then you need goals!

View Course »

Socially Responsible Investing

Invest in companies with a conscience.

View Course »

Add a Comment

*0 / 3000 Character Maximum